Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
- HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
- Celldex believes her deep background in drug development strongly complements the current Board’s skills and experiences.
- Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
- The litigation settlement related loss had a ($0.32) impact on net loss per share for the twelve months ended December 31, 2022.